VANCOUVER, B.C.--(BUSINESS WIRE)--March 1, 2001--Angiotech (NASDAQ:ANPI)(TSE:ANP.)
Angiotech Pharmaceuticals, Inc. (NASDAQ:ANPI)(TSE:ANP.) announced today that it has completed enrollment of its 189-patient, Phase 2 clinical study for the use of Micellar Paclitaxel in the treatment of patients with secondary progressive multiple sclerosis (SPMS).
To date, there have been no drug-related serious adverse events reported in the patients enrolled in the nine-month study.
The double-blind, placebo-controlled study is being conducted at nine centers across Canada. The primary objective of the study is to determine the difference in new lesion activity in the Micellar Paclitaxel treatment groups relative to the control group during the treatment phase as demonstrated by magnetic resonance imaging (MRI). Patients are receiving placebo or Micellar Paclitaxel at 50 mg/m2 or 75 mg/m2 every four weeks for a total of six doses (with a 12-week follow-up period).
"This major milestone has been completed in a timely manner and we are very proud of this accomplishment. We are hopeful that our Micellar Paclitaxel therapy will improve the quality of life for a group of patients with few treatment options," said Donald E. Longenecker, PhD, Angiotech's President and COO.
Multiple sclerosis is a chronic inflammatory and progressive disease, with debilitating neurological symptoms occurring over a period of several years. Although the disease does not result in early death, it disables patients by disturbing vision, strength, balance and sensation, as well as causing fatigue and cognitive problems. The estimated 2000 U.S. treatment market for all MS patients is US$704 million.
Angiotech Pharmaceuticals, Inc. is a Canadian pharmaceutical company dedicated to the development of medical device coatings and treatments for chronic inflammatory diseases through reformulation of the anticancer drug, paclitaxel. Four pharmaceutical therapies are in clinical development: systemic Micellar Paclitaxel for secondary progressive multiple sclerosis (Phase 2), rheumatoid arthritis (Phase 1) and severe psoriasis, and Topical Paclitaxel Gel for psoriasis (Phase 1). The paclitaxel-coated coronary stent program has also entered human safety studies. Other medical device programs include paclitaxel-loaded surgical implants for the treatment of restenosis associated with peripheral vascular surgery and for the treatment of proliferative ocular conditions.
herein that are not based on historical fact, including without limitation
statements containing the words "believes," "may," "will," "estimate,"
"continue," "anticipates," "intends," "expects" and words of similar import,
constitute "forward-looking statements" within the meaning of the U.S.
Private Securities Litigation Reform Act of 1995. Such forward-looking
statements involve known and unknown risks, uncertainties and other factors
that may cause the actual results, events or developments to be materially
different from any future results, events or developments expressed or
implied by such forward-looking statements. Such factors include, among
others, the following: general economic and business conditions, both nationally
and in the regions in which the Company operates; technology changes; competition;
changes in business strategy or development plans; the ability to attract
and retain qualified personnel; existing governmental regulations and changes
in, or the failure to comply with, governmental regulations; liability
and other claims asserted against the Company; and other factors referenced
in the Company's filings with the Securities and Exchange Commission. Given
these uncertainties, readers are cautioned not to place undue reliance
on such forward-looking statements. The Company disclaims any obligation
to update any such factors or to publicly announce the result of any revisions
to any of the forward-looking statements contained herein to reflect future
results, events or developments.
Angiotech Pharmaceuticals Inc.
Cathryn E. Hunter, 604/221-7676